SYSTEMATIC REVIEW article
Front. Neurol.
Sec. Stroke
Comparison of tenecteplase vs alteplase in addition to thrombectomy in patients with ischemic stroke caused by large vessel occlusion within 4.5h: a network meta-analysis
Provisionally accepted
- Chongqing Three Gorges Central Hospital, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The optimal reperfusion approach for acute ischemic stroke (AIS) due to large vessel occlusion (LVO) remains under debate. While endovascular thrombectomy (EVT) is the standard treatment, the role of intravenous thrombolysis before EVT— particularly with alteplase or tenecteplase—remains under investigation. This network meta-analysis (NMA) aimed to compare the efficacy and safety of three strategies: EVT alone, alteplase with EVT, and tenecteplase with EVT. Methods: A comprehensive search of Web of Science, PubMed, Cochrane Library and Embase was performed to find randomized controlled trials (RCTs) comparing the above interventions in AIS patients with LVO treated within 4.5 hours of symptom onset. A Bayesian NMA framework was used to estimate pooled effects. The primary endpoint was Proportion of patients achieving a modified Rankin Scale (mRS) score of 0–2 at 90 days. Secondary endpoints included mRS 0–1, symptomatic intracerebral hemorrhage (sICH), and 90-day mortality. Results: Seven RCTs involving 2793 patients were included. Among them, 1290 received EVT alone, 1124 alteplase with EVT, and 379 tenecteplase with EVT. Tenecteplase with EVT was associated with a higher rate of functional independence (mRS 0–2) at 90 days versus EVT alone (OR: 1.52; 95% CrI: 1.00–2.36), with the lower bound of the credible interval at the null. Tenecteplase with EVT also numerically outperformed alteplase plus EVT (OR: 1.48; 95% CrI: 0.97–2.36), although this difference was not statistically significant. No significant differences were observed among treatments in achieving excellent outcome (mRS 0 – 1), symptomatic intracerebral hemorrhage, or mortality. Tenecteplase plus EVT ranked highest in efficacy probability based on SUCRA values, but these rankings should be interpreted cautiously given the limited tenecteplase sample size and modest precision of the estimates. Conlusion: Tenecteplase with EVT may be associated with better 90-day functional outcomes than EVT alone and may offer advantages compared to alteplase with EVT for AIS patients with LVO treated within 4.5 hours, without an observed excess risk of sICH or mortality. However, these findings are based on a small number of tenecteplase-treated patients and borderline credible intervals, so they should be interpreted cautiously and confirmed in larger, rigorously designed randomized trials.
Keywords: Acute Ishemic Stroke, alteplase (rt-PA), Meta analys, Tenecteplase (TNK), Thrombectomy
Received: 23 Oct 2025; Accepted: 12 Dec 2025.
Copyright: © 2025 Li, Wu, Li and Deng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Rong Deng
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.